Nordic Secondary Fund has acquired a stake in Norlase, a global ophthalmic medical device company focused on next-generation laser treatments for retinal and glaucoma diseases.

Target Company Overview

Norlase is an innovative global player in the ophthalmic medical device sector, focused on developing cutting-edge laser technologies for treating retinal and glaucoma diseases. With a strong emphasis on research and development, Norlase aims to enhance patient outcomes through advanced treatment solutions.

The company is supported by a team of distinguished professionals who are recognized leaders in ophthalmology, laser engineering, medical device innovation, and customer service. This assembly of expertise positions Norlase to effectively navigate the complexities of the medical device market and meet the evolving needs of healthcare providers and patients alike.

Industry Overview in the Ophthalmic Sector

The ophthalmic medical device industry is experiencing rapid growth, driven by an increasing incidence of eye disorders globally. Conditions such as glaucoma and retinal disea